Medical Information Only. Consult your healthcare provider before enrolling in any clinical trial.
Maine: below-average open trial sites
72 of 315 in-state trials are recruiting (23%); below the 37% national average by 14 percentage points.
According to ClinicalTrials.gov-derived indexes, Maine sits in the lower half of US states by in-state trial count (#45 of 52 states by registered in-state trial count).
Maine: 315 US clinical trials with in-state sites, 72 recruiting.
Maine has 315 registered US clinical trials with a study site in-state, 72 of them currently recruiting (below the 37% national average by 14 percentage points). 97 of these trials are in Phase 3 (late-stage) and 84 in Phase 2. The most frequently studied condition in Maine is Breast Cancer, with 19 linked trials.
Thin-volume Maine archive
Maine open-enrollment share is 23% (p4 of states with sites; national baseline 37%). Treat this page as a compact local index (thin-volume · low-open), then jump to recruiting trials or methodology rather than expecting hub-scale coverage.
Below-average open enrollment
Maine still shows 72 recruiting of 315 in-state trials (23% open), but below the 37% national average by 14 percentage points, so archived statuses weigh heavier than the national baseline.
- 23%
- open (below national share)
- 72
- still recruiting despite cool share
- 84
- Phase 2 rows in this footprint
- 19
- top: Breast Cancer
Recruiting share is below the 37% national average by 14 percentage points. Counts include every study with at least one recorded site in the state. Registry reference only, not medical advice.
Maine vs all states by indexed in-state trial count
Where this state's ClinicalTrials.gov site count sits among every state with at least one listed trial (coverage density, not care quality)
315 Top 87% more indexed trials than 13% of 52 states
States, banded by indexed in-state trial count
Each bar is a band; taller bars hold more states. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov · 2026-08-08
Key findings
What ClinicalTrials.gov does not surface for Maine on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Maine open-enrollment share sits below the national baseline.
72 of 315 in-state trials (22.9%) are recruiting, against 37% nationally (-14.1 percentage points). Counts include every study with at least one recorded site in the state.
-
Maine trial sites spread across 8 city hubs.
Portland lists 105 of 315 in-state trials (33.3%) across 34 named facilities. Cities need five or more listed trials to appear here; locations are as filed by sponsors.
-
Breast Cancer is the most-studied condition in Maine.
19 of 315 in-state trials (6%) list Breast Cancer. That is a local concentration figure, not a national disease ranking.
-
Maine sponsorship is fragmented across many organizations.
Dana-Farber Cancer Institute appears on 15 of 315 in-state trials (4.8%). Sponsor identity is as filed on ClinicalTrials.gov.
-
Most Maine indexed trials have already finished enrollment.
171 of 315 (54.3%) are completed. The open share above is the remainder that still lists recruiting.
By Status
| Status | Trial count |
|---|---|
| Completed | 171 |
| Recruiting | 72 |
| Active | 72 |
By Phase
| Phase | Trial count |
|---|---|
| Phase 3 | 97 |
| Phase 2 | 84 |
| NA | 57 |
| Phase 1 | 19 |
| Phase 4 | 17 |
| Early Phase 1 | 1 |
Top Conditions
Top Sponsors
Where trials run in Maine
Portland carries 105 of Maine's 315 indexed trials (33%) across 34 named sites, ahead of Scarborough at 83. 8 cities clear five listed trials, together naming 121 distinct sites.
| City | Trials | Listed sites |
|---|---|---|
| Portland | 105 | 34 |
| Scarborough | 83 | 33 |
| Bangor | 34 | 16 |
| Auburn | 28 | 11 |
| Brewer | 14 | 7 |
| Augusta | 13 | 6 |
| Westbrook | 11 | 7 |
| Lewiston | 11 | 7 |
Distinct trials and named sites per city, as filed with ClinicalTrials.gov; cities under five trials omitted. Vintage 2026-08-08.
Open-share low
Maine open-enrollment share is 23% (p4 of states with sites; national baseline 37%).
Maine: open share sits in the low tercile of states
Sites spread across 8 cities with five or more listed trials, led by Portland (105, 33% of the state total) and Scarborough (83), together naming 121 distinct research locations.
Phase mix: 97 Phase 3 vs 84 Phase 2 (balanced across stages).
Top condition: Breast Cancer (19 trials); top sponsor Dana-Farber Cancer Institute (15).
thin-volume · low-open figures (315 trials · 23% open) describe registry geography under the open-share low read, not clinic capacity or protocol fit. Confirm status on ClinicalTrials.gov before acting.
States near Maine on open-enrollment share
Cross-state peers under the open-share low read (thin-volume · low-open), not the same-state browse list.
Similar thin-volume peers (± open share)
- West Virginia · 277 trials · 36% recruiting
- South Dakota · 273 trials · 31% recruiting
- North Dakota · 235 trials · 19% recruiting
- Vermont · 191 trials · 31% recruiting
- New Hampshire · 471 trials · 33% recruiting